Phase 2 Friedreich’s Ataxia Trial Given Green Light in Spain

According to a story from BioSpace, the biotechnology company Minoryx Therapeutics recently announced that the company has received official approval from the Spanish Agency of Medicines and Medical Devices (AEMPS)…

Continue Reading Phase 2 Friedreich’s Ataxia Trial Given Green Light in Spain
First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug
source: pixabay.com

First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug

According to a publication from Multiple Sclerosis News Today, German biotechnology company Immunic Therapeutics has successfully enrolled the first participant for its phase 2 clinical trial for experimental relapsing-remitting multiple…

Continue Reading First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug

Proof-of-Concept Trial for X-Linked Chronic Granulomatous Disease Treatment Shows Promise

According to a story from Markets Insider, the biopharmaceutical company Orchard Therapeutics recently announced the presentation of proof-of-concept data in regards to their investigational drug candidate OTL-102. This experimental therapy…

Continue Reading Proof-of-Concept Trial for X-Linked Chronic Granulomatous Disease Treatment Shows Promise
Observational Study Conducts Long Term Follow up of Niemann-Pick Disease Type B Patients
kropekk_pl / Pixabay

Observational Study Conducts Long Term Follow up of Niemann-Pick Disease Type B Patients

A study published in the Orphanet Journal of Rare Diseases monitored the long-term progression of 16 patients that had Niemann-Pick Disease type B. The study served to gather important observational data…

Continue Reading Observational Study Conducts Long Term Follow up of Niemann-Pick Disease Type B Patients
Close Menu